Attenuation of benzodiazepine dependence in mice by a tri-substituted benzoflavone moiety of Passiflora incarnata Linneaus: A non-habit forming anxiolytic

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 6, Issue 2, 2003, Pages 215-222

  Dhawan, Kamaldeep ^a   Dhawan, Sanju ^b   Chhabra, Sumit ^c  

^a Government of Haryana   (India)

^b PANJAB UNIVERSITY   (India)

^c MAHARSHI DAYANAND UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANXIOLYTIC AGENT; AROMATASE; BENZODIAZEPINE; BENZOFLAVONE DERIVATIVE; CANNABINOID; DIAZEPAM; LORAZEPAM; METHANOL; MORPHINE; NICOTINE; NITRAZEPAM; PASSIFLORA INCARNATA EXTRACT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CHRONIC TOXICITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG ISOLATION; DRUG MEGADOSE; DRUG WITHDRAWAL; ENZYME INHIBITION; FEMALE; INSOMNIA; MALE; MOBILIZATION; MOUSE; NONHUMAN; PHOTOMETER; PHYSICAL ACTIVITY; RECORDING; TRANQUILIZING ACTIVITY; WITHDRAWAL SYNDROME;

ANIMALS; ANTI-ANXIETY AGENTS; BENZODIAZEPINES; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MICE; PASSIFLORA; PLANT EXTRACTS; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 0141541771     PISSN: 14821826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Baldessarini, R.J., Drugs and the treatment of psychiatric disorders. In, Hardman, J.G. and Limbird, L.E. (editors) Goodman & Gilman's The Pharmacological Basis of Therapeutics. The McGraw-Hill Companies, New York, the USA: 399-427, 1996.
2. Longo, L.P. and Johnson, B., Addiction: Part I. Benzodiazepines: Side effects, abuse risk and alternatives. American Family Physician, 61: 2121-2128, 2000.
3. Lader, M.H., Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified? European Neuropsychopharmacology, 9 (Suppl 6): S399-S404, 1999.
4. Rickels, K. , Case, W. G. , Downing, R. W. and Winokur, A., Long-term diazepam therapy and clinical outcome. Journal of American Medical Association, 250: 767-771, 1983.
5. Woods, J.H., Katz, J.L. and Winger, G., Abuse liabilities of benzodiazepines. Pharmacology Reviews, 39: 251-413, 1987.
6. Ashton, H., Benzodiazepine withdrawal: an unfinished story. British Medical Journal, 288: 1135-40, 1984.
7. Busto, U., Sellers, E.M., Naranjo, C. A., Cappell, H. P., Sanchez, C. M. and Sykora, K., Withdrawal reaction after long-term therapeutic use of benzodiazepines. New England Journal of Medicine, 315: 654-59, 1986.
8. O'Brien, C. P., Drug Addiction and Drug Abuse. Wonsiewicz, M.J. and McCurdy, P. (eds). In:. Goodman & Gilman's The Pharmacological Basis of Therapeutics. The McGraw-Hill Companies, Inc., Nashville, Tennessee: 572-573, 1996.
9. Ernst, E., The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Annals of Internal Medicine, 136: 42-53, 2002.
10. Dechamp, J. F., Herbal Medicinal Products and Patient's Needs in Europe. Drug Information Journal, 33: 309-313, 1999.
11. Bartram, T., Encyclopedia of Herbal Medicine. Ed Grace Publishers, Dorset, England: Through http://www.raintree. com/maracuja.htm, 1995.
12. Blumenthal, M., Busse, W.R., Goldberg, A., Gruenwald, J., Hall, T., Riggins, C.W. and Rister, R. S. (eds.), Therapeutic Guide to Herbal Medicines. The American Botanical Council, Austin; copyright of Integrative Medicine Communications, Boston: 1998.
13. Reynolds, J.E.F. (ed), Martindale, The Extra Pharmacopoeia. Royal Pharmaceutical Society, London: 1738, 1996.
14. Passionflower, British Herbal Pharmacopoeia. British Herbal Medicine Society, Exeter, England: 154, 1983.
15. Passionbluenkraut, Deutsches Arzneibuch. Deutscher Apotheker Verlag., Stuttgart: 1997.
16. Passionflower, The Homoeopathic Pharmacopoeia of United States. American Institute of Homoeopathy, Arlington, VA: 440, 1981.
17. Passiflora incarnata, Homoeopathic Pharmacopoeia of India. Ministry of Health, Government of India, New Delhi: 116-117, 1974.
18. Dhawan, K., Kumar, S. and Sharma, A., Comparative biological activity study on Passiflora incarnata and P. edulis. Fitoterapia, 72: 698-702, 2001.
19. Dhawan, K., Kumar, S. and Sharma, A., Anxiolytic activity of aerial and underground parts of Passiflora incarnata. Fitoterapia, 72: 922-926, 2001.
20. Dhawan, K. and Sharma, A., Antitussive activity of the methanol extract of leaves of Passiflora incarnata. Fitoterapia, 73: 399-401, 2002.
21. Dhawan, K., Kumar, S. and Sharma, A., Anti-asthmatic activity evaluation of methanol extract of leaves of Passiflora incarnata. Phytotherapy Research, Manuscript No. PhyRes/2001/ 168 (in press): 2003.
22. Dhawan, K., Malik, J., Kumar, S. and Sharma, A., Aphrodisiac activity of methanol extract of leaves of Passiflora incarnata in mice. Phytotherapy Research, PhyRes/2001/000108 (in press): 2003.
23. Dhawan, K., Kumar, S. and Sharma, A., Antianxiety studies on extracts of Passiflora incarnata Linneaus. Journal of Ethnopharmacology, 78: 165-170, 2001.
24. Dhawan, K., Kumar, S. and Sharma, A ., Passiflora incarnata Linn.: A Promising Anxiolytic and Sedative - Isolation of a benzoflavone moiety as the bioactive agent. Presentation at the 42nd Annual Meeting of the American Society of Pharmacognosy, July 14-18, 2001, at Oaxaca, Mexico., Published in the Abstract Book as Oral Presentation - 29, 2001.
25. Dhawan, K., Kumar, S. and Sharma, A., Attenuation of drug/substance dependence by a novel tri-substituted benzoflavone moiety from Passiflora incarnata Linneaus. New Brunswick, New Jersey: 43rd Annual Meeting of the American Society of Pharmacognosy and 3rd Monroe Wall Symposium, July 28 - 31, 2002. Published in the Abstract Book as Oral Presentation -16, 2002.
26. Dhawan, K., Kumar, S. and Sharma, A., Reversal of tolerance and dependence of morphine by Passiflora incarnata Linneaus- A traditional medicine to combat morphine addiction. Pharmaceutical Biology (International Journal of Pharmacognosy), 40: 576-580, 2002.
27. 9-THC ) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linneaus in mice: a possible therapy for marihuana addiction. Journal of Pharmacy and Pharmacology, 54: 875-881, 2002.
28. Dhawan, K., Kumar, S. and Sharma, A., Nicotine reversal effects of the benzoflavone moiety from Passiflora incarnata Linneaus in mice. Addiction Biology, 7: 435-442, 2002.
29. Dhawan, K., Kumar, S. and Sharma, A., Suppression of alcohol-cessation-oriented hyper-anxiety by the benzoflavone moiety of Passiflora incarnata Linneaus in mice. Journal of Ethnopharmacology, 81: 239-244, 2002.
30. Dhawan, K., Kumar, S. and Sharma, A., Beneficial Effects of Chrysin and Benzoflavone on Virility in 2- Year-Old Male Rats. Journal of Medicinal Food, 5: 43-47, 2002.
31. Dhawan, K., and Sharma, A., Prevention of chronic alcohol and nicotine-induced azospermia, sterility and decreased libido, by a novel tri-substituted benzoflavone moiety from Passiflora incarnata Linneaus in healthy male rats. Life Sciences, 71: 3059-3069: 2002.
32. 9 THC-induced decline in sexuality in male rats by a novel benzoflavone moiety of Passiflora incarnata Linn. British Journal of Pharmacology, 138: 117-120, 2003.
33. Vogel, H. G. and Vogel, W. H., Drug Discovery and Evaluation, Pharmacological Assays. Springer-Verlag, Germany, Heidelberg: 1997.
34. Kulkarni, S.K. and Sharma, A., Reversal of diazepam withdrawal induced hyperactivity in mice by BR 16-A (Mentat), a herbal preparation. Indian Journal of Experimental Biology, 32: 886-888, 1994.
35. Farnsworth, N. R., Biological and Phytochemical Screening of Plants. Journal of Pharmaceutical Sciences, 55: 225-286, 1966.
36. Kulkarni, S.K. and Reddy, D.S., Animal Behavioral Models for Testing Antianxiety Agents. Methods and Findings in Experimental and Clinical Pharmacology, 18: 219-240, 1996.
37. Bolton, S., Pharmaceutical Statistics, Practical and Clinical Applications. Marcel Dekker, Inc., 270, Madison Avenue, NY, the United States of America, New York: 516-521, 1990.
38. Woods, J.H., Katz, J. L. and Winger, G., Abuse liability of benzodiazepines. Pharmacology Reviews, 39: 251-419, 1987.
39. Madden, J.S., Psychiatric advances in the understanding and treatment of alcohol dependence. Alcohol and Alcoholism, 19: 339-353, 1984.
40. Roelofs, S.M., Hyperventilation, anxiety, craving for alcohol: a subacute alcohol withdrawal syndrome. Alcohol, 2: 501-505, 1985.
41. Boerngen-Lacerda, R. and Souza-Formigoni, M.L., Does the increase in locomotion induced by ethanol indicate its stimulant or anxiolytic properties? Pharmacology Biochemistry and Behavior, 67: 225-232, 2000.
42. Dawson, G. R., Crawford, S. P., Collinson, N., Iversen, S. D. and Tricklebank, M. D., Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus-maze are confounded by increases in locomotor activity. Psychopharmacology (Berlin), 118: 316-323, 1995.
43. Reisine, T. and Pasternak, G., Opiod analgesics and antagonists. In: Hardmann, J.G., Limbird, L.E., Molinoff, P.B., Ruddon, R.W. and Gilman, A.G., (eds). The Pharmacological Basis of Therapeutics. MacGraw Hill, New York: 521-556, 1996.
44. Yamamoto, Y., Isoyama, E., Sofikitis, N. and Miyagawa, I, Effects of smoking on testicular function and fertilizing potential in rats. Urology Research, 26: 45-48, 1998.
45. Tentler, J.J., LaPaglia, N., Steiner, J., Williams, D., Castelli, M., Kelley, M.R., Emanuele, N.V. and Emanuele, M.A., Ethanol, growth hormone and testosterone in peripubertal rats. Journal of Endocrinology, 152: 477-487, 1997.
46. Block, R.I., Farinpour, R. and Schlechte, J.A., Effects of chronic marijuana use on testosterone, luteinizing hormone, follicle stimulating hormone, prolactin and cortisol in men and women. Drug Alcohol Dependence, 28: 121-128, 1991.
47. Dong, E., Matsumoto, K. and Watanabe, H., Diazepam binding inhibitor reduces testosterone and estradiol levels in vivo. Life Science, 70: 1317-1323, 2002.
48. Sanbuissho, A., Terada, S., Suzuki, K., Masuda, N., Teranishi, M. and Masuda, H., Male reproductive toxicity study of nitrazepam in rats. Journal of Toxicology Science, 20: 319-328, 1995.
49. Leung, M., Drug-Induced sexual dysfuntion: assessment and management in men and women. Pharmacy Connects, Copyright © Rogers Media, Toronto: Web site http://www.pharmacyconnects.com/pharprac/contact.html, through e-mail: pharmacypracticeμhpublishing.com, 1998.
50. Moerck, H.J. and Majelung, G., Gynaecomastia and diazepam abuse. Lancet, : 1344-1345, 1979.
51. Chopra, I.C., Drug Addiction. Indian Journal of Pharmacology, 3: 43-50, 1971.
52. Kishi, K., Kanamori, S., Maruyama, T., Sasaki, K., Hara, K., Kawai, M. and Ikeuchi, K., Potential parameters of male reproductive toxicity: reproductive performance, histopathology and sperm evaluation in SD rats given nitrazepam. Journal of Toxicology Science, 20: 329-339, 1995.
53. Calvo, D.J., Campos, M.B., Calandra, R.S., Medina, J.H. and Ritta, M.N., Effect of long term diazepam administration on testicular benzodiazepine receptors and steroidogenesis. Life Science, 49: 519-525, 1991.
54. Gavish, M., Hormonal regulation of peripheral-type benzodiazepine receptors. Journal of Steroid Biochemistry and Molecular Biology, 53: 57-59, 1995.
55. Frye, C.A., The role of neurosteroids and non-genomic effects of progestins and androgens in mediating sexual receptivity of rodents. Brain Research Reviews, 37: 201-222, 2001.
56. Primus, R.J. and Kellogg, C.K., Developmental influence of gonadal function on the anxiolytic effect of diazepam on environment-related social interaction in the male rat. Behavior Pharmacology, 1: 437-446, 1990.
57. Cooper, M. A. and Ritchie, E.C., Testosterone replacement therapy for anxiety. American Journal of Psychiatry, 157: 1884, 2000.
58. Roberts, A.J. and Koob, G.F., The Neurobiology of Addiction: An Overview. Alcohol Health & Research World, 21: 101-106, 1997.
59. Reddy, D. S. and Kulkarni, S. K ., Differential anxiolytic effects of neurosteroids in the mirrored chamber behavior test in mice. Brain Research, 752: 61-71, 1997.
60. Reilly, M. T., Crabbe, J.C., Rustay, N.R. and Finn, D.A., Acute neuroactive steroid withdrawal in withdrawal seizure-prone and withdrawal seizure-resistant mice. Pharmacology Biochemistry and Behavior, 67: 709-717, 2000.
61. Lambert, J.J., Belelli, D., Hill-Venning, C. and Peters, J.A., Neurosteroids and GABA-A receptor function. Trends in Pharmacological Science, 16: 295-303, 1995.
62. Majewska, M.D., Neurosteroids: endogenous bimodal modulators of the GABA-A receptor mechanism of action and physiological significance. Progresses in Neurobiology, 38: 379-395, 1992.
63. Gee, K.W., McCauley, L.D. and Lan, N.C., A putative receptor for neurosteroids on the GABA-A receptor complex: the pharmacological properties and therapeutic potential of epalons. Critical Reviews in Neurobiology, 9: 207-227, 1995.
64. Kao, Y.C., Zhou, C., Sherman, M., Laughton, C.A. and Chen, S., Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: A site-directed mutagenesis study. Environmental Health Perspective, 106: 85-92, 1998.
65. Kellis, J.T. and Vickery, L.E., Inhibition of estrogen synthetase (aromatase) by flavones. Science, 225: 1032-1033, 1984.
66. Lee, H.S., Jin, C., Park, J. and Kim, D.H., Involvement of P-4503A4 in the metabolism of 7,8-benzoflavone by human liver microsomes. Xenobiotica, 24: 1053-1062, 1994.
67. Guengerich, F.P., CYTOCHROME P-450 3A4: Regulation and Role in Drug Metabolism. Annual Reviews in Pharmacology and Toxicology, 39: 1-17, 1999.
68. Lee, H.S., Jin, C., Park, J. and Kim, D.H., Modulation of cytochrome P450 activities by 7,8-benzoflavone and its metabolites. Biochemistry and Molecular Biology International, 34: 483-491, 1994.
69. Robertson, K.M., Donnell, L.O., Jones, M.E., Meachem, S.J., Boon, W.C., Fisher, C.R., Graves, K.H., McLachlan, R.I. and Simpson, E.R., Impairment of spermatogenesis in mice lacking a functional aromatase (cyp 19) gene. Developmental Biology, 96: 7986-7991, 1999.
70. Sharpe, R. M., Natural and anthropogenic environmental oestrogens: the scientific basis for risk assessment - Environmental oestrogens and male infertility. Pure & Applied Chemistry, 70: 1685-1701, 1998.
71. Lam, M., Andropause. through www.DrLam.com and drΔrLam.com, 2001.
72. Crémoux, P., Aromatase inhibitors: pharmacological aspects. Bulletin du Cancer, 87: 23-30, 2000.
73. Chen, S., Kao, Y.C. and Laughton, C. A., Binding characteristics of aromatase inhibitors and phytoestrogens to human aromatase. Journal of Steroid Biochemistry and Molecular Biology, 61: 107-115, 1997.
74. Cohen, R., Estrogen - The Unrecognized Male Hormone. International Antiaging Systems, Les Autelets Suite A, Sark GY9 0SF, Channel Islands, Great Britain: through http://www.smart-drugs.com, 2001.
75. Merken, H. M. and Beecher, G. R., Finessing the Flavonoids: A part of Human Nutrition, an ARS National Program. U. S. Government Printing Office, Beltsville, MD: 2001.
76. Lader, M., Treatment of anxiety. British Medical Journal, 309: 321-324, 1994.